233 related articles for article (PubMed ID: 14597556)
1. The LPS receptor (CD14) links innate immunity with Alzheimer's disease.
Fassbender K; Walter S; Kühl S; Landmann R; Ishii K; Bertsch T; Stalder AK; Muehlhauser F; Liu Y; Ulmer AJ; Rivest S; Lentschat A; Gulbins E; Jucker M; Staufenbiel M; Brechtel K; Walter J; Multhaup G; Penke B; Adachi Y; Hartmann T; Beyreuther K
FASEB J; 2004 Jan; 18(1):203-5. PubMed ID: 14597556
[TBL] [Abstract][Full Text] [Related]
2. LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide.
Liu Y; Walter S; Stagi M; Cherny D; Letiembre M; Schulz-Schaeffer W; Heine H; Penke B; Neumann H; Fassbender K
Brain; 2005 Aug; 128(Pt 8):1778-89. PubMed ID: 15857927
[TBL] [Abstract][Full Text] [Related]
3. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology.
Hao W; Liu Y; Liu S; Walter S; Grimm MO; Kiliaan AJ; Penke B; Hartmann T; Rübe CE; Menger MD; Fassbender K
Brain; 2011 Jan; 134(Pt 1):278-92. PubMed ID: 21115468
[TBL] [Abstract][Full Text] [Related]
4. TLR2 is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory activation.
Liu S; Liu Y; Hao W; Wolf L; Kiliaan AJ; Penke B; Rübe CE; Walter J; Heneka MT; Hartmann T; Menger MD; Fassbender K
J Immunol; 2012 Feb; 188(3):1098-107. PubMed ID: 22198949
[TBL] [Abstract][Full Text] [Related]
5. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern.
Letiembre M; Liu Y; Walter S; Hao W; Pfander T; Wrede A; Schulz-Schaeffer W; Fassbender K
Neurobiol Aging; 2009 May; 30(5):759-68. PubMed ID: 17905482
[TBL] [Abstract][Full Text] [Related]
6. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.
Heneka MT; Sastre M; Dumitrescu-Ozimek L; Hanke A; Dewachter I; Kuiperi C; O'Banion K; Klockgether T; Van Leuven F; Landreth GE
Brain; 2005 Jun; 128(Pt 6):1442-53. PubMed ID: 15817521
[TBL] [Abstract][Full Text] [Related]
7. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J
J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
Fabbro S; Schaller K; Seeds NW
J Neurochem; 2011 Sep; 118(5):928-38. PubMed ID: 21689108
[TBL] [Abstract][Full Text] [Related]
9. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system.
Vollmar P; Kullmann JS; Thilo B; Claussen MC; Rothhammer V; Jacobi H; Sellner J; Nessler S; Korn T; Hemmer B
J Immunol; 2010 Nov; 185(10):6338-47. PubMed ID: 20943998
[TBL] [Abstract][Full Text] [Related]
10. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.
Simard AR; Soulet D; Gowing G; Julien JP; Rivest S
Neuron; 2006 Feb; 49(4):489-502. PubMed ID: 16476660
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease.
Simard AR; Rivest S
Mol Psychiatry; 2006 Apr; 11(4):327-35. PubMed ID: 16491130
[TBL] [Abstract][Full Text] [Related]
13. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide.
Townsend KP; Town T; Mori T; Lue LF; Shytle D; Sanberg PR; Morgan D; Fernandez F; Flavell RA; Tan J
Eur J Immunol; 2005 Mar; 35(3):901-10. PubMed ID: 15688347
[TBL] [Abstract][Full Text] [Related]
14. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease.
Kalinin S; Gavrilyuk V; Polak PE; Vasser R; Zhao J; Heneka MT; Feinstein DL
Neurobiol Aging; 2007 Aug; 28(8):1206-14. PubMed ID: 16837104
[TBL] [Abstract][Full Text] [Related]
15. Targeting the hematopoietic system for the treatment of Alzheimer's disease.
Lampron A; Gosselin D; Rivest S
Brain Behav Immun; 2011 Jun; 25 Suppl 1():S71-9. PubMed ID: 21195165
[TBL] [Abstract][Full Text] [Related]
16. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
Vodopivec I; Galichet A; Knobloch M; Bierhaus A; Heizmann CW; Nitsch RM
Neurodegener Dis; 2009; 6(5-6):270-80. PubMed ID: 20145420
[TBL] [Abstract][Full Text] [Related]
17. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease.
Walter S; Letiembre M; Liu Y; Heine H; Penke B; Hao W; Bode B; Manietta N; Walter J; Schulz-Schuffer W; Fassbender K
Cell Physiol Biochem; 2007; 20(6):947-56. PubMed ID: 17982277
[TBL] [Abstract][Full Text] [Related]
18. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?
Dragicevic N; Bradshaw PC; Mamcarz M; Lin X; Wang L; Cao C; Arendash GW
Neuroscience; 2011 Jun; 185():135-49. PubMed ID: 21514369
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells.
Bate C; Kempster S; Williams A
Neuropharmacology; 2006 Feb; 50(2):229-37. PubMed ID: 16289250
[TBL] [Abstract][Full Text] [Related]
20. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
